Oligosymptomatic neurosyphilis with false negative CSF-VDRL in HIV-infected individuals?

Eur J Med Res. 1996 Mar 19;1(6):299-302.

Abstract

The true prevalence of neurosyphilis in HIV-infection is unknown, since a sufficiently sensitive and specific test is lacking. In a prospective study we found reactive serum TPHA and FTA-ABS IgG tests in 95 (31%) of 307 HIV-infected patients. Three of 11 patients with latent syphilis revealed reactive CSF-VDRL tests, six others only demonstrated CSF abnormalities. Resolution of CSF abnormalities during a six month follow up after high dose antibiotic therapy led to the diagnosis of oligosymptomatic or asymptomatic neurosyphilis in all nine patients. Thus, the specificity of the CSF-VDRL was 100%, but the sensitivity was only 33%. The overall prevalence of neurosyphilis was 2.9%, increasing to 9.5% in patients with a reactive serum TPHA. Our study emphasizes the importance of antibiotic therapy for presumptive neurosyphilis in HIV-infected patients with latent syphilis and CSF abnormalities but nonreactive CSF-VDRL tests, even if they are neurologically asymptomatic or present with complaints inconclusive of neurosyphilis.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / therapeutic use
  • Cardiolipins / cerebrospinal fluid*
  • Cholesterol / cerebrospinal fluid*
  • Erythromycin / therapeutic use
  • False Negative Reactions
  • HIV Infections / complications*
  • HIV Seropositivity / complications*
  • Humans
  • Male
  • Middle Aged
  • Neurosyphilis / complications
  • Neurosyphilis / diagnosis*
  • Neurosyphilis / drug therapy
  • Neurosyphilis / epidemiology
  • Penicillin G / therapeutic use
  • Penicillins / therapeutic use
  • Phosphatidylcholines / cerebrospinal fluid*
  • Prevalence
  • Reproducibility of Results
  • Sensitivity and Specificity

Substances

  • Anti-Bacterial Agents
  • Cardiolipins
  • Penicillins
  • Phosphatidylcholines
  • VDRL antigen
  • Erythromycin
  • Cholesterol
  • Penicillin G